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Phthalates including di-(2-ethylhexyl)  phthalate 
(DEHP) and di-isononyl phthalate are added 
to polyvinyl plastic materials to increase flex-
ibility. Phthalates can be released into food 
during processing and from packing material, 
with food believed to be the main source of 
human exposure (Wormuth et al. 2006). In 
addition, a number of cosmetic compounds 
contain diethyl phthalate (DEP) and/or di-n-
butyl phthalate (DBP). These phthalates can 
cross the human skin after application and 
thereby represent an additional source of 
exposure (Janjua et al. 2008). Several million 
tons of phthalates are used worldwide every 
year (Wormuth et al. 2006).
The elimination half-life of phthalate 
metabolites from the human body is rela-
tively fast, with a half-life of < 24 hr for most 
metabolites (Koch et al. 2006). However, 
because of continuous exposure, phthalates 
can be detected in almost all studied human 
samples. In Germany, the estimated phthalate 
intake has been reported to exceed accept-
able daily intake for about 14% of the popu-
lation (Wittassek et al. 2007).
Rodent studies indicate that exposure to 
specific phthalates may induce female repro-
ductive toxicity. In a continuous breeding 
protocol on mice, a reduction in the number 
of litters, litter size, and proportion of liveborn 
offspring was observed after DEHP exposure 
as well as after exposure to higher concentra-
tions of DBP (Lamb et al. 1987), whereas 
increased risk of mid-pregnancy abortions was 
found among DBP-exposed rats in another 
study (Gray et al. 2006; Lamb et al. 1987). 
However, the concentrations of phthalate 
used in these rodent studies were > 100 times 
higher than the average estimated daily intake 
for the general population (Frederiksen et al. 
2011). So far, phthalate exposure in women 
has not been associated with measures of 
fertility. However, an association between 
increased phthalate level and precocious 
breast development has been observed (Colon 
et al. 2000). Moreover, phthalate exposure 
among adult women has been associated with 
endometriosis (Cobellis et al. 2003) and ges-
tational duration, although with inconsistent 
results (Adibi et al. 2009; Latini et al. 2003; 
Wolff et al. 2008).
In humans, about one-third of all preg-
nancies terminate before the fetus is fully 
developed, and about two-thirds of these 
are lost early in pregnancy at the embryonic 
stage (Wilcox et al. 1988). Few environmen-
tal causes of early pregnancy loss have been 
established, but recent studies indicate that 
environmental contaminants [e.g., dichloro-
diphenyltrichloroethane (DDT) exposure 
(Venners et al. 2005)] and lifestyle factors 
such as alcohol consumption (Henriksen 
et al. 2004) and physical strain (Hjollund 
et al. 2000b) may increase the risk of early 
pregnancy loss. To date, no studies have 
investigated the association between preg-
nancy loss and phthalate exposure in human 
populations.
The extensive use of phthalates together 
with the possible effects on human health 
makes it important to develop methods to 
assess exposure. Phthalates are rapidly hydro-
lyzed to the biologically active monoesters in 
the body and excreted in the urine (Wittassek 
and Angerer 2008). Thus, monoethyl phtha-
late (MEP) is a marker of DEP, monobenzyl 
phthalate (MBzP) of benzyl butyl phthalate 
(BBzP), and monobutyl phthalate (MBP) 
mainly of DBP and BBzP. Finally, mono-
ethylhexyl phthalate (MEHP) is a marker 
of DEHP exposure (Anderson et al. 2001). 
In addition, MEHP is further oxidized to 
hydroxy-MEHP and oxo-MEHP. Techniques 
using liquid chromatography–tandem mass 
spectrometry (LC/MS/MS) have provided 
rapid methods for measuring these metabo-
lites in urine (Blount et al. 2000).
We examined the association between 
phthalate exposure during pregnancy attempts 
and pregnancy loss, including both early bio-
chemical detectable losses and abortions of 
clinically recognized pregnancies.
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Ba c k g r o u n d: Animal studies indicate that some phthalate metabolites may harm female 
  reproductive function.
oBjectives: We assessed the associations between exposure to phthalate metabolites and pregnancy 
loss.
Me t h o d s : Using a previously established cohort of couples planning their first pregnancy, we 
analyzed four primary and two oxidized secondary phthalate metabolites in urine samples collected 
on day 10 after the first day of the last menstrual period before conception occurred (n = 128) and 
during the previous cycle (if any, n = 111). Subclinical embryonal loss was identified by repeated 
measurement of urinary human chorionic gonadotropin, and information on clinical spontaneous 
abortions was obtained by telephone interview with the mother.
re s u l t s: Pregnancy loss (n = 48) was increased among women with urinary concentration of 
monoethylhexyl phthalate (MEHP) in the upper tertile in the conception sample compared with 
women in the lowest tertile [adjusted odds ratio (OR) = 2.9; 95% confidence interval (CI): 1.1, 
7.6]. The corresponding OR for subclinical embryonal loss (n = 32) was 40.7 (95% CI: 4.5, 369.5).
co n c l u s i o n s: The phthalate metabolite MEHP was associated with higher occurrence of preg-
nancy loss. Because this is the first human study to show this association and the sample size is 
small, the findings need to be corroborated in independent studies.
key w o r d s : abortion, MEHP, phthalates, pregnancy loss. Environ Health Perspect 120:458–463 
(2012).  http://dx.doi.org/10.1289/ehp.1103552 [Online 23 November 2011]Phthalates and pregnancy loss
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Methods
From 1992 to 1994, a total of 430 couples 
were enrolled in a Danish prospective cohort 
study of fecundity after a nationwide mailing 
of personal letters to > 50,000 members of 
four trade unions (Bonde et al. 1998). Letters 
were sent to union members who were 20–35 
years of age, lived with a partner of the oppo-
site sex, and had no children. Only couples 
without any knowledge about their reproduc-
tive capacity and who planned to stop contra-
ception to conceive were invited to participate. 
They were enrolled when birth control was 
discontinued and followed prospectively until 
a clinically recognized pregnancy occurred, or 
for six menstrual cycles if there was no clinical 
pregnancy. A crude estimate of the participa-
tion rate, based on an estimation of the eli-
gible population, has been calculated as 16% 
(Bonde et al. 1998). The women filled in a 
diary with menstrual cycle data and produced 
a urine sample each day of the first 10 days of 
each menstrual cycle until a pregnancy was 
achieved, or for a maximum of six cycles. In 
addition, the women and their partners filled 
in a detailed questionnaire on occupation and 
health, and the outcome of each pregnancy 
was ascertained by an interview after 1 year 
(Bonde et al. 1998; Hjollund et al. 2000a).
All urine samples from the first day of 
the vaginal bleeding period were analyzed for 
the content of human chorionic gonadotro-
pin (hCG) by an immunofluorometric assay 
(DELFIA, Wallace, Finland). This method 
is specific for intact hCG and was validated 
for measurements of hCG in urine. Serial 
dilutions of urinary samples resulted in a lin-
ear response curve parallel to the standard 
curve. For 12 women not reporting any inter-
course for the preceding 2 months, all urinary 
hCG measurements were below the detec-
tion limit of 0.5 IU/L. If the hCG level was 
> 0.8 IU/L in a sample from the first day after 
vaginal bleeding, the following nine samples 
were analyzed as well (Bonde et al. 1998). 
Early pregnancy loss was considered to have 
occurred if any of the hCG values from one 
menstrual cycle was > 1 IU/L, followed by a 
decline in the hCG level.
In 2009, at least one series of stored 
urine samples was available for 242 of the 
430 women who were enrolled in the preg-
nancy planner study. In 77 women, no urine 
samples were collected because conception 
occurred during the first menstrual cycle. 
In addition, some samples (n = 111) were 
lost during the storage period for unknown 
reasons. Age and average amounts of smok-
ing and drinking were very similar between 
women with and without analyzed samples; 
but waiting time to pregnancy was shorter 
and the proportion of couples achieving a 
pregnancy after 12 months was higher among 
women without phthalate measurements, 
because this group included a large propor-
tion of women who became pregnant in the 
first menstrual cycle (data not shown). From 
each of the women with available urine sam-
ples, we selected up to two urine samples for 
analysis of phthalate metabolites (Figure 1), 
including one conception sample from day 
10 after the first day of the last menstrual 
period before their first pregnancy (registered 
as either a clinical pregnancy or hCG eleva-
tion) (n = 128), and one pre  conception sam-
ple from day 10 of the previous menstrual 
period termed, when available (n = 111).
The final sample comprised 128 women 
with a pregnancy during the study period and 
at least one urinary phthalate analysis available, 
including 80 who had a pregnancy that ended 
with the birth of a liveborn child and 48 who 
had a pregnancy loss, including 32 identified 
by hCG elevations only. Women who did 
not become pregnant during the study period 
(n = 114) were not at risk of pregnancy loss 
and were excluded from the analysis.
Pregnancy loss was defined as the loss of a 
pregnancy identified based on hCG elevation 
after menstrual bleeding only (classified as an 
early pregnancy loss) or the loss of a clinical 
pregnancy recognized by the woman’s general 
practitioner (spontaneous abortion or later 
pregnancy loss).
All participants in the study signed 
informed consent when enrolled in the study, 
and the study (including the additional uri-
nary analysis of phthalates) was approved by 
the ethical committee of the Central Region, 
Denmark.
Exposure assessment. The urine samples were 
processed using an automated solid-phase extrac-
tion technique and analyzed by LC/MS/MS. 
Briefly, after adding internal standards, the 
samples were treated with glucuronidase to 
remove glucuronic acid and acidified, and the 
metabolites were extracted using Oasis HLB 
3 mL (60 mg) on an Aspec XL4 automated 
solid-phase extraction equipment (Gilson, 
Middleton, WI, USA). The samples were 
then evaporated and dissolved in water con-
taining acetic acid. 2H4-MEP, 2H4-MBP, 
2H4-MEHP, 13C4-MBzP, 13C4-5-hydroxy-
MEHP, and 13C4-5-oxo-MEHP were used 
as internal standards. The MS parameters, 
precisions, and detection limits are shown 
in Supplemental Material, Table 1 (http://
dx.doi.org/10.1289/ehp.1103552). Values for 
MBP and hydroxy-MEPH were within the 
tolerance limits obtained in samples from a 
round-robin interlaboratory control program 
from the University of Erlangen–Nürnberg, 
Germany. However, measured values deviated 
from the tolerance limits for oxo-MEHP. A 
possible explanation for this has been indi-
cated by the Erlangen group: The standards 
from Cambridge Isotope Laboratories used in 
the analysis have been described as having up 
to 60% different concentrations in different 
batches. No interlaboratory control programs 
were available for the other compounds. In 
each series, an internal control urine sample 
was analyzed, and there was no temporal 
variation in the measured concentrations of 
any of the metabolites in the control sample. 
A hand refractometer was used to determine 
urine density. To calculate density-adjusted 
urine concentrations, the following formula 
was used: Ccorr = Cobs × 0.016/(ρ–1), where 
Ccorr is the corrected concentration, Cobs is the 
observed concentration and ρ is the specific 
density of the urine sample (Boeniger et al. 
1993). Except for 15 samples that had MEHP 
levels below the limit of detection (LOD; 
2 ng/mL), all selected phthalate metabolites 
were detected in all the measured urine sam-
ples. The actual readout from the LC/MS/MS 
was used for values below the LOD.
Statistical methods. We estimated the 
odds ratios (ORs) for pregnancy loss accord-
ing to urinary phthalate metabolite con-
centration grouped into tertiles by logistic 
regression. Results were presented separately 
according to exposure in the preconception 
and the conception cycle to evaluate whether 
associations differed according to the prox-
imity of the exposure measurement to the 
time of fertilization. To assure the same expo-
sure limits between tertiles in the two sets of 
analyses, data analyses were based on tertiles 
Figure 1. Overview of the timing of selected samples for phthalate analyses in relation to time of concep-
tion, hCG analysis, and ascertainment of clinical pregnancy. The times given represent averages in the 
study population.
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calculated from the exposure distribution in 
the conception cycle. 
Furthermore, separate logistic models 
were used to estimate associations with early 
pregnancy loss (hCG determined) and later 
pregnancy loss compared with women who 
became pregnant and did not experience a 
pregnancy loss. These analyses were performed 
to evaluate whether early loss was more sensi-
tive to phthalate exposure than losses occur-
ring later in the pregnancy.
In the logistic regression models, we 
adjusted for potential confounders suspected 
to influence female risk of pregnancy loss [age 
(continuous), body mass index (BMI) (low 
< 20; medium 20–25, and high > 25 kg/m), 
smoking (cigarettes/day, continuous; non-
smokers = 0 cigarettes/day), alcohol consump-
tion (units/weeks, continuous), caffeine intake 
(milligrams caffeine/day, continuous)] and 
exposure to the individual measured chemicals 
in the pre  conception cycle for analyses based on 
the conception cycle and vice versa (exposure 
grouped in tertiles). We considered p < 0.05 
(two-tailed tests) statistically significant. All data 
analyses were performed with SAS version 9.1 
(SAS Institute Inc., Cary, NC, USA).
Results
Exposure distributions for the measured 
phthalate metabolites in the conception cycle 
are shown in Table 1. Among all women in 
the study, we found the highest exposure to 
MEP ranging from 19.3 to 2782.8 ng/mL, 
followed by MBP (11.8–1005.0 ng/mL), 
which is considerably higher than values for 
the secondary MEHP metabolites 5-oxo-
MEHP (2.7–245.9 ng/mL) and 5-hydroxy-
MEHP (3.6–215.3 ng/mL), followed by 
MBzP (0.8–173.5 ng/mL) and MEHP 
(< LOD–84 ng/mL). Of 15 MEHP samples 
< LOD, 6 were found on samples from the 
conception cycle (two from women with 
pregnancy loss and four from women not 
experiencing a pregnancy loss). The correla-
tion between samples from the conception 
and preconception cycle was 0.40 for MEP, 
0.28 for 5-oxo-MEHP, 0.27 for 5-hydroxy-
MEHP, 0.20 for MBP, 0.17 for MBzP, and 
0.08 for MEHP.
The average MEHP exposure in the 
conception cycle was significantly different 
between women experiencing a pregnancy loss 
and those who did not experience a pregnancy 
loss [23.4 ng/mL (range, < LOD–84.0) vs. 
16.2 ng/mL (range, < LOD–64.0)], whereas 
the other measured phthalate metabolites did 
not differ significantly (Table 1). On average, 
women who had a pregnancy loss smoked 
fewer cigarettes per day and had a tendency 
toward higher caffeine consumption than did 
women without a pregnancy loss, but other 
potential confounders were similar between 
the outcome groups. The distributions of 
potential confounders were similar according 
to MEHP exposure tertiles in the conception 
cycle [see Supplemental Material, Table 2 
(http://dx.doi.org/10.1289/ehp.1103552)] 
except for the average number of cigarettes 
smoked, which was the highest in the middle 
tertile (4.4/day vs. 1.4 and 1.5/day in the low-
est and highest tertiles, respectively).
The association of measured phthalate expo-
sure in the pre  conception cycle with pregnancy 
loss was not statistically significant (Table 2). 
However, MEHP in the conception sample 
was significantly associated with pregnancy loss 
[adjusted OR = 2.87; 95% confidence interval 
(CI): 1.09, 7.57 for the third tertile compared 
with the first tertile, p = 0.03)] (Table 2). Crude 
ORs were generally consistent with adjusted 
ORs. The highest tertiles of all of the other 
measured phthalate metabolites in the concep-
tion samples were also associated with preg-
nancy loss, but ORs were not significant.
Of the 48 pregnancy losses included in 
this study, 32 were detected by hCG elevation 
before gestational week 6, whereas the remain-
ing 16 were lost later in the pregnancy. When 
Table 1. Distribution of phthalate metabolites in the cycle where women achieved a pregnancy and 
  covariates among women experiencing loss of an hCG-detected or a clinical pregnancy and women 
  carrying a pregnancy to term.
Phthalate exposure and potential confounders
Pregnancy loss 
(n = 48)
Liveborn child 
(n = 80)
p-Value for 
differencea
Phthalate exposure [mean (minimum, maximum)]
MEP (ng/mL) 377.6 (27.9, 2765.9) 405.8 (19.3, 2782.8) 0.77
MBP (ng/mL) 255.1 (37.7, 955.4) 225.6 (11.8, 1005.0) 0.39
MBzP (ng/mL) 21.1 (2.4, 173.5) 20.3 (0.8, 117.0) 0.87
MEHP (ng/mL) 23.4 (< LOD, 84.0) 16.2 (< LOD, 64.0) 0.01
5-hydroxy-MEHP (ng/mL) 51.9 (9.5, 207.1) 43.2 (3.6, 215.3) 0.18
5-oxo-MEHP (ng/mL) 48.6 (5.7, 245.9) 40.3 (2.7, 222.2) 0.22
Potential confounders [mean (minimum, maximum) or %]
Age at enrollment in the study.  25.5 (19.0, 32.0) 25.3 (21.0, 35.0) 0.73
Alcohol (drinks/week)  4.2 (0, 25) 5.8 (0, 35) 0.16
Smoking (cigarettes/day)  1.1 (0,17.0) 3.3 (0, 20) 0.04
Caffeine intake (milligrams caffeine/day)  350 (56, 1,006) 280 (0, 1,017) 0.09
BMI < 20.0 kg/m 27 23 0.84
BMI 20.0–25.0 58 61
BMI > 25.0 15 16
at-Test for continuous data and chi-square test for categorical data.
Table 2. ORs (95% CIs) for pregnancy loss according to tertiles of density-adjusted spot urine concentration of phthalate metabolites in the menstrual cycle 
  preceding a conception (preconception cycle) and in the cycle where women achieved a pregnancy (conception cycle). 
First tertile Second tertile Third tertile
Phthalate metabolite n (% loss)a  OR n (% loss)a OR crude OR adjb n (% loss)a OR crude OR adjb
Preconception cycle
MEP 18 (44) 1 12 (39) 0.81 (0.31, 2.09) 0.93 (0.35, 2.50) 14 (36) 0.72 (0.29, 1.76) 0.81 (0.31, 2.09)
MBP 17 (49) 1 13 (33) 0.51 (0.20, 1.30) 0.70 (0.27, 1.84) 14 (39) 0.67 (0.26, 1.73) 0.79 (0.32, 2.00)
MBzP 9 (43) 1 22 (48) 1.22 (0.43, 3.46) 1.38 (0.53, 3.62) 13 (30) 0.56 (0.19, 1.65) 0.59 (0.21, 1.65)
MEHP 23 (45) 1 14 (30) 0.53 (0.23, 1.23) 0.74 (0.30, 1.82) 7 (54) 1.42 (0.42, 4.82) 1.79 (0.47, 6.81)
5-hydroxy-MEHP 16 (48) 1 15 (43) 0.84 (0.32, 2.19) 1.33 (0.51, 3.40) 13 (30) 0.46 (0.17, 1.18) 0.57 (0.22, 1.48)
5-oxo-MEHP 17 (43) 1 18 (51) 1.43 (0.58, 3.56) 2.01 (0.80, 5.04) 9 (25) 0.45 (0.17, 1.20) 0.46 (0.16, 1.34)
Conception cycle
MEP 14 (33) 1 16 (37) 1.46 (0.60, 3.57) 1.51 (0.57, 3.98) 18 (42) 1.61 (0.66, 3.92) 1.98 (0.74, 5.34)
MBP 15 (36) 1 16 (37) 1.07 (0.44, 2.58) 1.12 (0.41, 3.02) 17 (40) 1.18 (0.49, 2.83) 1.12 (0.43, 2.95)
MBzP 13 (31) 1 17 (40) 1.56 (0.60, 3.57) 1.72 (0.63, 4.69) 18 (42) 1.61 (0.66, 3.92) 2.10 (0.74, 5.88)
MEHP 13 (31) 1 12 (28) 0.86 (0.34, 2.20) 0.97 (0.34, 2.76) 23 (53) 2.57 (1.06, 6.23) 2.87 (1.09, 7.57)
5-hydroxy-MEHP 15 (36) 1 14 (33) 0.87 (0.35, 2.13) 0.94 (0.34, 2.59) 19 (44) 1.43 (0.60, 3.41) 1.46 (0.56, 3.78)
5-oxo-MEHP 14 (33) 1 17 (40) 1.31 (0.54, 3.17) 1.22 (0.46, 3.27) 17 (40) 1.31 (0.54, 3.18) 1.38 (0.51, 3.74)
Tertiles are based on exposure distribution in the conception cycle.
aLoss of an hCG-detected or clinical pregnancy in this tertile (percentage loss/all pregnancies). bAdjusted (adj) for age, BMI, smoking, alcohol consumption, caffeine consumption, and 
exposure to the specific compound analyzed in the preconception cycle for the analyses based on the conception cycle and vice versa.Phthalates and pregnancy loss
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we analyzed early and later pregnancy loss 
separately, early pregnancy loss was increased 
for the third tertile of MEHP exposure in the 
conception sample compared with the first 
tertile, with only one case of early pregnancy 
loss at the lowest MEHP tertile (OR = 40.67; 
CI: 4.48, 369.50); late pregnancy loss was 
inversely associated with MEHP (OR = 0.25; 
CI: 0.05, 1.8 and OR = 0.17; CI: 0.03, 0.95 
for the third and second tertiles compared 
with the first, respectively) based on two cases 
in the second and the third tertile (Table 3). 
None of the other phthalate metabolites were 
statistically significantly associated with early 
or late pregnancy loss in the separate analysis, 
but several were positively associated with 
early pregnancy loss.
Discussion
In our study we found a statistically signifi-
cant association between elevated periconcep-
tional MEHP exposure and pregnancy loss. 
Furthermore, subanalyses found that early loss 
of a pregnancy was more frequent at higher 
MEHP exposure, although because of a lim-
ited number in this group, the estimated OR 
was associated with a wide CI. The remarkably 
low incidence of early pregnancy loss (3%) in 
the low MEHP exposure group suggests that 
the highly elevated OR for early pregnancy loss 
may be attributable, at least partly, to chance 
findings. Pregnancy loss was not significantly 
associated with other metabolites in the con-
ception sample or with any of the phthalate 
metabolites in the preconception sample.
Determining loss of a pregnancy by 
hCG elevation is considered very accurate. 
Urine samples for hCG analysis were miss-
ing in 21% of the cycles, mainly for logistical 
reasons. Because of missing sample collec-
tion, some early pregnancy losses might not 
have been identified. However, this is not 
likely to be associated with either exposure or 
probability of early pregnancy loss. Clinical 
pregnancies were determined by the gen-
eral practitioner 2 weeks, on average, after a 
missed menstrual period, and information 
on the outcome of the pregnancy was col-
lected for all reported clinical pregnancies. 
Therefore, we do not suspect misclassification 
of the clinical pregnancies.
Participants in our study had no prior 
knowledge about their fecundity, because only 
first pregnancy planners who had used contra-
ception were included. Thus, it is unlikely 
that couples with known problems related to 
fertility were selected. Even if the included 
cohort was different from the background 
population in relation to fecundity, the par-
ticipants had no knowledge about phthalate 
exposure and were probably not taking any 
precautions to avoid these chemicals, as the 
potential harmful effects of phthalates were 
not discussed in the public in the early 1990s 
when couples were enrolled for the present 
study. Therefore, selection bias is unlikely. 
Although the participation rate was only 
approximately 16% and our study population 
was not a representative sample of the general 
population (Bonde et al. 1998), we have no 
reason to believe that the associations between 
phthalate exposure and pregnancy loss would 
be different in another sample of female preg-
nancy planners. The exclusion in the pres-
ent study of highly fertile couples achieving 
a pregnancy in the first menstrual cycle after 
discontinuation of contraception, where urine 
samples were not collected before pregnancy 
occurred, limited the external validity of the 
study, and if the highly fecund women were 
less sensitive to phthalate exposure, our results 
may be an overestimate of the risk for the gen-
eral population. Also, because of the design of 
our study, we were not able to evaluate the 
association between phthalate exposure and 
pregnancy loss on the subfecund couples who 
did not achieve a pregnancy within the study 
period of 6 months, which might underesti-
mate the effects in the general population if 
the subfecund couples were more sensitive to 
phthalate exposure.
An unexpected finding was an inverse 
association between MEHP exposure and 
late pregnancy loss (Table 3). This might be 
explained by a strong effect of MEHP on early 
loss leading to elimination of vulnerable preg-
nancies that would be aborted later because 
of other causes. This phenomenon of appar-
ently protective effects on later reproductive 
events of exposures with adverse effects on 
early outcomes is well known in reproduc-
tive toxicology (Selevan and Lemasters 1987). 
Alternatively, it may be speculated that mis-
classification of etiologically relevant exposure 
is larger for loss of clinical pregnancies if the 
losses are induced by exposure later in preg-
nancy. This would make the study less able 
to detect associations between exposure and 
loss of clinical pregnancies and could explain, 
in part, the lack of a positive association with 
clinical pregnancies. However, the remark-
ably low incidence of early pregnancy loss 
(3%) and the unexpected high rate of loss of 
clinical pregnancies (29%) in the low MEHP 
exposure group suggests that the positive asso-
ciation between MEHP exposure and early 
pregnancy loss and the inverse association 
of MEHP with loss of clinical pregnancies 
may also, at least partly, reflect random error 
because of the limited sample size.
Rodent studies support adverse repro-
ductive effects of MEHP. Lamb et al. (1987) 
tested the effects of DEP, DBP, dihexyl 
phthalate, and DEHP on the number of lit-
ters and proportion of liveborn offspring in 
mice. They found that DEHP (which is rap-
idly metabolized to MEHP and secondary 
metabolites in mammals) reduced the number 
of litters and proportion of liveborn offspring 
Table 3. Analysis of MEHP divided into separate analysis of early embryonal loss and later pregnancy loss in the cycle where women achieved a pregnancy 
[OR (95% CI)]. 
First tertile Second tertile Third tertile
Phthalate exposure n (% loss)a OR n (% loss)a OR crude OR adjb n (%) lossa OR crude OR adjb
Early pregnancy loss
MEP 12 (26) 1 12 (32) 1.34 (0.50, 3.61) 1.29 (0.43, 3.83) 10 (29) 1.16 (0.42, 3.23) 1.13 (0.36, 3.59)
MBP 9 (25) 1 10 (27) 1.11 (0.39, 3.17) 1.25 (0.38, 4.09) 13 (33) 1.50 (0.54, 4.10) 1.64 (0.52, 5.20)
MBzP 7 (19) 1 12 (32) 1.91 (0.66, 5.59) 2.39 (0.70, 8.22) 13 (34) 2.15 (0.74, 6.24) 3.11 (0.87, 11.09)
MEHP 1 (3) 1 10 (24) 9.36 (1.13, 77.71) 10.83 (1.16, 101.48) 21 (51) 30.45 (3.78, 245.06) 40.67 (4.48, 369.50)
5-hydroxy-MEHP 8 (23) 1 10 (26) 1.16 (0.40, 3.38) 1.05 (0.31, 3.56) 14 (37) 1.97(0.70, 5.50) 2.12 (0.67, 6.67)
5-oxo-MEHP 6 (18) 1 13 (33) 2.33 (0.77, 7.04) 2.16 (0.63, 7.39) 13 (33) 2.33 (0.77, 7.04) 2.73 (0.78, 9.54)
Loss of clinical pregnancy
MEP 3 (11) 1 5 (16) 1.86 (0.40, 8.55) 2.19 (0.42, 11.45) 8 (24) 3.09 (0.74, 12.93) 4.63 (0.92, 23.26)
MBP 6 (18) 1 6 (18) 1.00 (0.29, 3.49) 0.87 (0.21, 3.57) 4 (13) 0.69 (0.18, 2.74) 0.51 (0.12, 2.21)
MBzP 6 (17) 1 5 (16) 0.93 (0.25, 3.41) 1.08 (0.25, 4.66) 5 (17) 0.97 (0.26, 3.55) 0.96 (0.20, 4.59)
MEHP 12 (29) 1 2 (6) 0.16 (0.03, 0.76) 0.17 (0.03, 0.95) 2 (9) 0.24 (0.05, 1.20) 0.25 (0.05, 1.28)
5-hydroxy-MEHP 7 (21) 1 4 (12) 0.53 (0.14, 2.02) 0.91 (0.19, 4.16) 5 (17) 0.80 (0.23, 2.87) 0.90 (0.23, 3.61)
5-oxo-MEHP 8 (22) 1 4 (13) 0.54 (0.15, 2.00) 0.55 (0.13, 2.29) 4 (13) 0.54 (0.15, 2.00) 0.55 (0.13, 2.35)
Tertiles are based on exposure distribution in the conception cycle.
aLoss in this tertile (percentage loss/all pregnancies). bAdjusted (adj) for age, BMI, smoking, alcohol consumption, caffeine consumption, and exposure to the specific compound 
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when mixed as 0.1% or 0.3% of the diet, 
whereas DBP had effects at 1% of the diet 
and DEP had no apparent effects up to 2.5% 
of the diet (Lamb et al. 1987). DEHP has also 
been shown to induce postimplantation loss 
after exposure of male rats at 750 mg/kg/day 
(Jarfelt et al. 2005). Similarly, DBP (metab-
olized to MBP) has been found to act as a 
reproductive toxicant in female rats, where 
fetuses were spontaneously aborted in mid-
pregnancy and hormone levels were altered 
in female rats exposed to 500 μg/kg/day DBP 
or higher (Gray et al. 2006). However, the 
effects in these animal studies were observed 
after exposures higher than the estimated daily 
intake for human populations, which typically 
is in the low micrograms per kilogram range 
(Frederiksen et al. 2011).
Based on animal studies, a mechanism of 
action of phthalates on female reproductive 
function can be suggested. In rats, DEHP 
exposure decreased the levels of estrogen and 
progesterone (Svechnikova et al. 2007) in 
addition to prolonging menstrual cycles and 
anovulation. These disturbances, based on 
in vitro experiments, can be explained by a 
DEHP-induced decrease in aromatase mRNA 
and protein levels, causing decreased conver-
sion of testosterone to estradiol (Lovekamp-
Swan and Davis 2003). Because low estradiol 
and progesterone levels have been associated 
with human fetal loss (Schindler 2004), the 
association between MEHP and pregnancy 
loss in our study population might reflect a 
phthalate-induced decrease in the secretion of 
these hormones.
In the conception cycle, non  significantly 
higher ORs for pregnancy loss were found 
at the third tertile in the conception sample 
for all of the measured phthalate metabo-
lites. A tendency toward similar associations 
with MEHP and MEHP metabolites may 
be explained by a high correlation between 
MEHP and secondary metabolites (r > 0.8), 
but the other measured phthalate metabo-
lites were only weakly correlated with MEHP 
(r < 0.2). Potential effects of these compounds 
are therefore unlikely to be explained by cor-
relation with MEHP.
In the present study, the correlation of 
different phthalate metabolites between pre-
conception sample and conception samples 
was between 0.08 and 0.40, indicating that 
individual phthalate exposure is highly 
variable over time (Anderson et al. 2001). 
Therefore, it is not surprising that we found 
associations between phthalate exposure and 
pregnancy loss only when we included the 
sample taken a few days before conception, 
because we did not expect delayed effects on 
implantation and embryonic development. 
Even when measured close to the event of 
interest, there could have been misclassifi-
cation of the exposure due to the interday 
variation in the urinary concentration of these 
compounds (Fromme et al. 2007) and impre-
cision of the analysis (Hoppin et al. 2006). 
In our study, the coefficient of variation of 
concentrations obtained in quality control 
samples varied between 7% and 34% [see 
Supplemental Material, Table 1 (http://
dx.doi.org/10.1289/ehp.1103552)]. Also, 
some variation in the ovulation day in the 
menstrual cycle is likely; therefore, some mea-
surements will be closer to ovulation than 
others, inducing additional risk of misclas-
sification of etiologically relevant exposure in 
some women. However, we do not expect this 
misclassification to be related to the outcome, 
because all samples were taken before the 
pregnancies occurred and analyzed without 
knowledge of the outcome. Therefore, this 
possible misclassification would most likely 
bias the results toward the null effect.
It can be questioned whether phthalate 
metabolites can be measured accurately in 
samples stored for several years. A recent 
study (Baird et al. 2010) indicated that 
phthalate metabolites can indeed be meas-
ured accurately on samples stored for approxi-
mately 22–24 years at –20°C. The authors 
reported that compared with recent samples, 
the stored samples contained higher concen-
trations, indicating no or only limited deg-
radation, although concentrations might 
have been higher in the past. The correla-
tions between metabolites and reproducibility 
between stored samples collected 2–4 weeks 
apart were similar to those of recent stud-
ies. Concentrations for a representative 
sample of Danish women are not available, 
but compared with representative samples 
from 60 American and 53 German women, 
with a concentration of MEHP of 8.3 and 
10.3 ng/mL, respectively (Baird et al. 2010; 
Koch et al. 2003), we measured higher con-
centrations of MEHP and higher or similar 
concentrations of other phthalate metabolites. 
We also found a very high correlation between 
MEHP secondary metabolites (5-oxo-MEHP 
and 5-hydroxo-MEHP: r > 0.94) and similar 
correlations as in previous studies between 
samples collected from the same individuals 
at different times (Baird et al. 2010; Koch 
et al. 2003), indicating that our samples were 
unlikely to have been affected by major degra-
dation during storage.
We included a number of potential con-
founders in our analysis (female age, BMI, 
smoking, alcohol consumption, and caffeine 
consumption). The self-reported lifestyle factors 
may have been recorded with some bias. Male 
exposure data were not available, which is a 
limitation if male exposures are also associated 
with spontaneous abortion and with female 
exposure. Sperm quality was not included as 
a potential confounder in the model, because 
it is unlikely that male semen quality is related 
to female phthalate exposure. Furthermore, 
we cannot exclude residual confounding from 
unmeasured potential confounders.
Our study takes advantage of the possibil-
ity of measuring exposure during a specific 
time window suspected to be of importance 
for pregnancy loss in a prospective study 
design. However, our study population was 
limited in size, and effect estimates for early 
pregnancy losses were imprecise. Therefore, 
the markedly elevated OR in this subanaly-
sis should be interpreted with caution. The 
findings need to be repeated in larger cohorts 
before final conclusions on the adverse effects 
of MEHP on pregnancy loss can be made.
Conclusions
We found associations between exposure to 
the phthalate metabolite MEHP in the period 
around conception and pregnancy loss; no 
associations were observed for exposures meas-
ured in the previous menstrual cycle. None 
of the other measured phthalate metabolites 
were significantly associated with pregnancy 
loss when measured close to conception or one 
cycle earlier. To our knowledge, this is the first 
study to show an association between phthalate 
exposure and pregnancy loss, and additional 
studies are needed to confirm these findings.
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